Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02743819 |
Title | Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | University of Chicago |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
University of South Alabama | Mobile | Alabama | 36604 | United States | Details | |
Mount Sinai Medical Center of Florida | Miami Beach | Florida | 33140 | United States | Details | |
H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | United States | Details | |
University of Chicago | Chicago | Illinois | 60637 | United States | Details | |
Decatur Memorial Hospital | Decatur | Illinois | 62526 | United States | Details | |
NorthShore University HealthSystem | Evanston | Illinois | 60201 | United States | Details | |
Oncology Specialists S.C. | Park Ridge | Illinois | 60068 | United States | Details | |
Illinois Cancer Care | Peoria | Illinois | 61615 | United States | Details | |
Fort Wayne Medical Oncology and Hematology, Inc. | Fort Wayne | Indiana | 46804 | United States | Details | |
Virginia Commonwealth University/ Massey Cancer Center | Richmond | Virginia | 23298 | United States | Details |